Novavax (NVAX) Reschedules Investor, Analyst Meeting; Wants to Finalize Resolve Trial Data

October 7, 2016 8:01 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Novavax, Inc., (Nasdaq: NVAX) announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.

“We continue to analyze data from our Resolve clinical trial and map out the clinical path forward for our older adult RSV F Vaccine in the context of our other clinical programs,” said Stanley C. Erck, President and CEO. “We would like to finalize those plans and communicate them at the same time as our third quarter financial results call in early November. We look forward to providing the next steps in our RSV F Vaccine program, as well as an update on the path forward for additional programs in our pipeline and our financial and operating plan, which we will provide as a dedicated part of our November financial results.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Related Entities

Davenport, Earnings

Add Your Comment